Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Drop in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 349,900 shares, a decline of 10.0% from the March 31st total of 388,800 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average trading volume of 278,000 shares, the short-interest ratio is presently 1.3 days.

Immix Biopharma Trading Up 2.4 %

Shares of Immix Biopharma stock opened at $2.17 on Wednesday. Immix Biopharma has a 52 week low of $1.40 and a 52 week high of $7.75. The stock has a market cap of $57.29 million, a PE ratio of -2.44 and a beta of 0.06. The company’s 50-day moving average price is $2.87 and its two-hundred day moving average price is $4.02.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings results on Friday, March 29th. The company reported ($0.24) earnings per share (EPS) for the quarter. On average, equities analysts predict that Immix Biopharma will post -0.91 EPS for the current fiscal year.

Institutional Trading of Immix Biopharma

Several large investors have recently added to or reduced their stakes in the company. OLD National Bancorp IN acquired a new stake in shares of Immix Biopharma in the fourth quarter worth $69,000. Tocqueville Asset Management L.P. acquired a new stake in Immix Biopharma during the 3rd quarter worth about $41,000. Jump Financial LLC purchased a new position in Immix Biopharma during the 4th quarter valued at about $128,000. Tritonpoint Wealth LLC acquired a new position in shares of Immix Biopharma in the 1st quarter valued at about $75,000. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Immix Biopharma by 26.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 28,855 shares of the company’s stock valued at $99,000 after purchasing an additional 6,030 shares during the period. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.